Northeast Investment Management Has $40.15 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Northeast Investment Management trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% in the first quarter, Holdings Channel.com reports. The institutional investor owned 81,692 shares of the medical research company’s stock after selling 1,143 shares during the period. Thermo Fisher Scientific makes up about 1.7% of Northeast Investment Management’s holdings, making the stock its 19th largest holding. Northeast Investment Management’s holdings in Thermo Fisher Scientific were worth $40,154,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of TMO. Assetmark Inc. boosted its stake in Thermo Fisher Scientific by 22.9% during the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after buying an additional 7,023 shares in the last quarter. Mackenzie Financial Corp lifted its holdings in shares of Thermo Fisher Scientific by 29.4% during the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock worth $134,130,000 after acquiring an additional 62,790 shares during the period. North Dakota State Investment Board acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $7,505,000. Quadrant Capital Group LLC increased its stake in Thermo Fisher Scientific by 30.9% in the third quarter. Quadrant Capital Group LLC now owns 14,277 shares of the medical research company’s stock valued at $6,924,000 after acquiring an additional 3,369 shares during the period. Finally, Fisher Asset Management LLC raised its position in Thermo Fisher Scientific by 1.2% in the third quarter. Fisher Asset Management LLC now owns 2,721,101 shares of the medical research company’s stock worth $1,319,789,000 after purchasing an additional 31,298 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Barclays lowered their price objective on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Wall Street Zen cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Finally, Morgan Stanley restated an “overweight” rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $608.95.

Insider Buying and Selling

In other news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $506.19 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $401.45 and a 52 week high of $643.99. The stock has a market capitalization of $188.11 billion, a PE ratio of 27.83, a PEG ratio of 2.18 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The stock’s fifty day moving average is $474.44 and its 200-day moving average is $520.23.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher is showcasing new AI-enabled, end-to-end biopharma tools at the BIO International Convention, including Orbitrap mass spectrometry upgrades, AI software, and integrated lab solutions, reinforcing its position as a full-service partner in drug development. Is Thermo Fisher (TMO) Quietly Redefining Its Edge With AI-Enabled, End-to-End Biopharma Tools?
• Positive Sentiment: Recent commentary highlighted support from Thermo Fisher’s long-range growth targets, Clario acquisition integration, and fresh analyst optimism, all of which can help lift the stock when investors are looking for visibility and execution upside. Thermo Fisher gains as investors weigh growth targets, Clario integration, and fresh analyst support
• Neutral Sentiment: Multiple industry pieces continued to position Thermo Fisher as a key player in fast-growing life sciences and lab services markets, which supports the broader investment thesis but is not a direct near-term catalyst. Global Laboratory Equipment Services Market Size/Share Worth USD 62.83 Billion by 2035
• Neutral Sentiment: Thermo Fisher’s Q1 earnings comparison article does not point to a new operational surprise, but it reinforces that the company has been delivering solid results relative to peers. Q1 Earnings Highlights: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.